Effect of Milrinone on Congenital Heart Disease Combined with Pulmonary Artery Hypertension and Congestive Heart Failure in Children Before Operation

XIE Li-jian,TENG Guo-tiang,ZHANG Yu-cai,QIU Gang,RONG Qun-fang,GONG Xiao-hui,ZHANG Yu-ming
2009-01-01
Abstract:Objective To investigate the effect of intravenous Milrinone on children with congenital heart disease (CHD) combined with pulmonary artery hypertension (PAH) and congestive heart failure (CHF) before operation.Methods Forty CHD children with PAH and CHF aged 1 month to 3 years were collected.All the 40 children were randomly divided into research group and control group.Each group had 20 children and there were no significant differences in disease,PAH,cardiac function and age.All children were treated with digoxin,diuretic and vasodilator.Twenty children in research group were also treated with intravenous Milrinone[0.5 μg/(kg·min)]and the other 20 children in control group were added with intravenous Dopamine and dobutamine [5 μg/(kg·min)].The cardiac function (systolic and diastolic function) and pulmonary artery pressure with echocardiography before drug treated,drug maintaining 72 h in vein and 2 h after drug treated were detected.Results The cardiac systolic and diastolic functions (cardiac index,left ventricular ejection fraction,left ventricular fractional shortening,right lentricalar systolic interval,right ventricular systolic time interphase and E/A] of Milrinone group were significantly better improved than those in control group (Pa0.05).Conclusions Milrinone has both inotropic and vasodilative effects.It will enable an ob-vious improvement on cardiac functions as well as pulmonary artery pressure.Intravenous Milrinone in CHD patients with CHF could give a good chance for operation.
What problem does this paper attempt to address?